Novo Nordisk A/S
Novo Nordisk A/S (NVO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NVO · as of Jun 8, 2026
Key Statistics
Explore Novo Nordisk A/S Data
nvo stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 39 · Buy rate: 59.0%
The NVO analyst consensus is Buy, based on ratings from 39 Wall Street analysts over the past 3 months. The average 12-month price target is $49.50, representing +17.96% upside from the current price of $41.97.
Competitors & Peers
nvo competitorsNVO
ABT
AMGN
AZN
GILD
GSKStock Performance
Full HistoryAbout Novo Nordisk A/S
Novo Nordisk A/S together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, …
what is novo nordisk a/s · nvo stock overview · novo nordisk a/s company profile · who is novo nordisk a/s ceo · nvo NYSE · novo nordisk a/s headquarters · novo nordisk a/s business segments
About Stock Overview & Key Data
Novo Nordisk A/S (NVO) is a Healthcare company in the Biotechnology industry, listed on NYSE since Apr 30, 1981. As of the latest trading session, NVO stock price is $41.97, with a market capitalization of $186.5B. The stock has returned -43.07% over the past 12 months and -15.57% year-to-date.
According to 39 Wall Street analysts, the consensus rating for Novo Nordisk A/S stock is Buy, with an average 12-month price target of $49.50. In fiscal year 2025, Novo Nordisk A/S reported revenue of $309.1B and net income of $102.4B. For detailed data — including Novo Nordisk A/S revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Novo Nordisk A/S (NVO) stock price is $41.97. The stock is traded on NYSE under the ticker symbol NVO. The 52-week range is $35.12 – $81.44.